Experimental HCV Drugs
Experimental HCV Drugs
CROI 2012: New Hepatitis C Drugs in Clinical Practice [VIDEO]
- Details
- Category: HCV Treatment
- Published on Wednesday, 07 March 2012 00:00
- Written by Gregory Fowler
New therapies are leading to a "huge sea change" in the way infectious disease doctors are thinking about hepatitis C, Douglas Dieterich suggested at a press conference at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
Hepatitis C Advocates Call for Early Studies of Interactions with New HCV Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 28 February 2012 00:00
- Written by HCAB
Experimental direct-acting antiviral agents for hepatitis C virus (HCV) should be tested for drug-drug interactions with antiretroviral agents for HIV and other medications commonly used by people with hepatitis C before they are combined with other drugs in clinical trials, according to a statement by an international Hepatitis C Community Advisory Board.
Hard-to-Treat Hepatitis C Patients Relapse after Stopping Interferon-Free GS-7977/Ribavirin Regimen
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 21 February 2012 00:00
- Written by Liz Highleyman
A majority of prior null responders with difficult-to-treat hepatitis C virus (HCV) genotype 1 experienced viral rebound after completing treatment with an all-oral regimen of the HCV nucleotide polymerase inhibitor GS-7977 plus ribavirin.
Good 12-Week HCV Suppression with Oral Telaprevir/VX-222/Ribavirin Combo
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 24 February 2012 00:00
- Written by Vertex Pharmaceuticals
More than 80% of previously untreated genotype 1 chronic hepatitis C patients treated with an all-oral triple regimen including the approved HCV protease inhibitor telaprevir (Incivek), the experimental non-nucleoside polymerase inhibitor VX-222, and ribavirin experienced full viral suppression after 12 weeks of therapy, Vertex reported this week.
FDA Lifts Hold on Idenix HCV Polymerase Inhibitor IDX184
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 07 February 2012 00:00
- Written by Idenix
The U.S. Food and Drug Administration (FDA) last week gave the go-ahead for further development of Idenix Pharmaceuticals' hepatitis C virus (HCV) nucleotide polymerase inhibitor IDX184. The agency lifted a hold imposed after a few healthy volunteers who received a combination of IDX184 plus another experimental agent, IDX321, in an early clinical trial developed elevated liver enzymes; further analysis indicates that liver toxicity is likely attributable to the second drug.
More Articles...
- High Rate of Sustained Response with Interferon-Free Daclatasvir + Asunaprevir for Hepatitis C
- Achillion, Presidio, Idenix Announce HCV Drug Pipeline Developments
- Pharmasset Halts Testing of HCV Polymerase Inhibitor PSI-938 Due to Liver Problems
- AASLD 2011: Recombinant Hepatitis C Vaccine TG404 Shows Promise in Phase 2 Trial
Web Design and Development by